Pandemic-induced delays in radical prostatectomy unlikely to cause adverse oncological outcomes
July 16th 2020In men who had radical prostatectomies for intermediate and high-risk disease, a delay of up to 12 months did not result in any worse outcomes compared to immediate surgery within 3 months of diagnosis.
PSMA PET/CT alters treatment approach in 66% of patients with recurrent prostate cancer
July 13th 2020The most frequent treatment changes triggered by 18F-DCFPyL PSMA PET/CT were a shift from observation or systemic therapy to surgery or radiation, or adding nodal-directed therapy to radiation or salvage surgery.
Sulopenem hits key end point in phase 3 uncomplicated UTI trial
June 29th 2020The novel oral penem anti-infective compound sulopenem showed stronger clinical activity than ciprofloxacin in patients with uncomplicated urinary tract infections with quinolone resistant pathogens, according to findings from the phase 3 SURE1 trial.
Consensus guideline for advanced prostate cancer released by AUA, ASTRO, and SUO
June 25th 2020The American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology have released a joint guideline for advanced prostate cancer to address the growing treatment options and complexity of the paradigm.
Ipatasertib plus abiraterone and prednisone delays progression in mCRPC with PTEN loss
June 19th 2020Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced castration-resistant prostate cancer whose tumors had PTEN loss.